{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '5.', 'TREATMENT ASSESSMENTS AND EVALUATIONS', '5.1', 'Recording of data', 'All data will be recorded in the electronic case report forms (eCRFs), which will be', 'maintained on secure servers at the SCCA and/or UWMC. Patient data will be de-identified,', 'and access to the de-identification key will only be available to the Principal Investigator and', 'his designees as necessary.', '5.2', 'Data collection at enrollment and follow-up', 'During the Treatment/Intervention Period study procedures and assessments must be done', 'within 7 days (+/-) of the specified study visit date unless otherwise noted. Screening', 'procedures and assessments must be done within 30 days prior to enrollment unless', 'otherwise noted. End of Study procedures and assessments must be within 30 days of', 'stopping study drug(s).', 'Note: If a subject withdraws from the study prior to the 12-week timepoint, the \"End of', 'Study\" procedures will be completed at the time of withdrawal.', '5.2.1', 'Screening (within 30 days of Cycle 1, Day 1)', '1. Informed consent', '2. Comprehensive medical history and physical exam, including height and weight,', 'medication reconciliation, blood pressure, heart rate and ECOG performance status', 'assessment', '3. CBC (Complete blood count) with differential and platelet count', '4. CMP (Comprehensive Metabolic Panel - Sodium, Potassium, Chloride, BUN,', 'Serum Creatinine, Calcium, Total Protein, Albumin, Total Bilirubin, AST, ALT,', 'Alkaline Phosphatase, CO2)', '5. PSA', '6. Testosterone', '7. Estradiol', '8. aPTT (activated partial thromboplastin time), PT/INR (prothrombin', 'time/international normalized ratio)', '40(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '9. Radiologic tests (i.e., CT chest/abdomen/pelvis and bone scan)', '10. ECG', '11. Metastatic biopsy', 'Note: If a biopsy cannot be safely performed, archival tissue obtained within the last', 'year may be used as long as patient had castration-resistant prostate cancer, as', 'determined by the treating physician, at that time.', '5.2.2', 'Treatment/Intervention Period', '1. Comprehensive medical history and physical exam, including weight, medication', 'reconciliation, blood pressure, heart rate and ECOG performance status assessment', '[Day 1 of every cycle]', '2. Olaparib dispensation [Day 1 of every cycle]', '3. Unused olaparib collection [Day 1 of every cycle beginning Cycle 2]', '4. Treatment with testosterone enanthate or testosterone cypionate [Day 1 of every', 'cycle]', '5. CBC (Complete blood count) with differential and platelet count [Day 1 of every', 'cycle]', '6. CMP (Comprehensive Metabolic Panel - Sodium, Potassium, Chloride, BUN,', 'Serum Creatinine, Calcium, Total Protein, Albumin, Total Bilirubin, AST, ALT,', 'Alkaline Phosphatase, CO2) [Day 1 of every cycle]', '7. PSA [Day 1 of every cycle]', '8. Testosterone [Cycle 1, Day 8 (+/- 7 days) and Cycle 2, Day 1]', '9. Estradiol [Cycle 1, Day 8 (+/- 7 days) and Cycle 2, Day 1]', '10. Radiologic tests (i.e. CT chest/abdomen/pelvis and bone scan) [Every 3 cycles', 'beginning Cycle 4, Day 1]', '41 1(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}